TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $28.00 at Cowen

TransMedics Group (NASDAQ:TMDX) had its price target decreased by Cowen from $40.00 to $28.00 in a research report report published on Thursday, The Fly reports. Cowen currently has an outperform rating on the stock.

Separately, Zacks Investment Research upgraded TransMedics Group from a sell rating to a hold rating in a report on Sunday, November 3rd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $33.00.

TransMedics Group stock traded up $0.34 during midday trading on Thursday, reaching $16.95. The company’s stock had a trading volume of 229,900 shares, compared to its average volume of 146,987. The company has a debt-to-equity ratio of 0.48, a quick ratio of 6.82 and a current ratio of 7.55. The company’s 50 day simple moving average is $19.50. TransMedics Group has a fifty-two week low of $15.74 and a fifty-two week high of $31.54.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.08. The business had revenue of $7.21 million during the quarter, compared to analysts’ expectations of $6.67 million. Sell-side analysts predict that TransMedics Group will post -2.25 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NumerixS Investment Technologies Inc acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $43,000. JPMorgan Chase & Co. acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $50,000. Tower Research Capital LLC TRC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $190,000. Blackstone Group Inc acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $290,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at about $314,000. 65.88% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Featured Story: Understanding Market Liquidity

The Fly

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.